2015-08-17T12:49:36-05:00 2014-12-31 420714325 MCGLADREY LLP 1 S WACKER DRIVE STE 800 CHICAGO IL 60606 990 2014-01-01 366009467 Orthopaedic Research and Education Foundation ORTH 8476989980 9400 W Higgins Road No 215 Rosemont IL 60018 Donna Rebeck Chief Financial Officer 8476989980 2015-08-17 1 Marek Rozowicz P01616027 3126343400 2014 2016-03-07 17:11:31Z X OREF Sharon Mellor 9400 W Higgins Road No 215 Rosemont IL 60018 18344390 0 X www.oref.com X 1955 IL Improving lives by supporting excellence in orthopaedic research. 23 23 19 70 0 0 6370076 4520407 0 0 1270492 1051728 0 0 7640568 5572135 4313800 2196778 0 0 1809388 1754587 87500 0 1209573 1301549 1181834 7512237 5133199 128331 438936 40971473 39669534 6462780 4517932 34508693 35151602 X The Orthopaedic Research and Education Foundation (OREF) mission is improving lives by supporting excellence in orthopaedic research. The Foundation's vision is that it will be the leader in supporting orthopaedic research to improve function, eliminate pain and restore mobility. 0 1 2815896 2126014 Grant Program The purpose of the Foundation is to support research into the causes and treatment of musculoskeletal diseases and injuries. OREF's niche is supporting surgeon-researchers and PhD-researchers in basic science/translation, clinical, and health services research. 176047 70764 For the new medical researcher in orthopaedics, OREF's education programs offer the opportunity to develop their research interests and skills. Through educational programming, OREF supports emerging talent to help them successfully pursue research careers. 2991943 1 1 0 0 0 0 0 0 1 1 1 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 20 0 1 19 1 0 0 0 0 0 1 1 0 0 0 0 X 23 23 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CT DC DE FL GA IL IN KS KY LA MA MD ME MI MS MN MO MT NC ND NE NJ NH NM NY OH OK OR PA RI SC SD TN UT VA WA WI WV WY X X Donna Rebeck 8476989980 9400 W Higgins Road Ste 215 Rosemont IL 600184975 John J Callaghan MD President 10.00 X X 0 0 0 David G Lewallen MD President-Elect 7.00 X X 0 0 0 Ramon L Jimenez MD Past President 7.00 X X 0 0 0 Richard J Haynes MD Secretary & Vice Chair, Development 7.00 X X 0 0 0 James G Borovsky Treasurer 7.00 X X 0 0 0 James D Heckman MD Vice Chair, Research Grants 7.00 X X 0 0 0 Frank B Kelly Jr MD Vice Chair, Educational Grants 7.00 X X 0 0 0 Thomas P Schmalzried MD Vice Chair, Corporate Relations 7.00 X X 0 0 0 S Terrance Canale MD Trustee 0.10 X X 0 0 0 R Tracy Ballock MD Trustee 0.10 X 0 0 0 James H Beaty MD Trustee 5.00 X 0 0 0 John A Bergfeld Trustee 5.00 X 0 0 0 Jeffrey R Binder Trustee 5.00 X 0 0 0 Kevin J Bozic MD Trustee 5.00 X 0 0 0 Matthew B Dobbs MD Trustee 5.00 X 0 0 0 Letha Griffin MD Trustee 5.00 X 0 0 0 Farshid Guilak PhD Trustee 5.00 X 0 0 0 John H Healey MD Trustee 5.00 X 0 0 0 Shepard R Hurwitz MD Trustee 5.00 X 0 0 0 Richard F Kyle MD Trustee 5.00 X 0 0 0 Adolph V Lombardi Jr MD FACS Trustee 0.10 X 0 0 0 William C McMaster MD Trustee 5.00 X 0 0 0 Michael L Parks MD Trustee 5.00 X 0 0 0 E Anthony Rankin MD Trustee 5.00 X 0 0 0 Richard Santore MD Trustee 5.00 X 0 0 0 Richard R Tarr Trustee 5.00 X 0 0 0 Sharon K Mellor PhD CAE Chief Executive Officer 50.00 X 201205 0 56028 Donna Rebeck CPA CAE CFO/COO 50.00 X 150344 0 49842 Edward Hoover Vice President for Development 40.00 X 115098 0 23794 Robert Payne - VP of Corporate Development&Strategic Philanthropy 40.00 X 107058 0 7528 573705 0 137192 4 0 1 0 0 4520407 171652 4520407 904836 904836 12919147 12772255 146892 146892 146892 5572135 0 0 1051728 2196778 2196778 457418 155522 100632 201264 885529 301080 194816 389633 159354 40714 40026 78614 158239 40884 49263 68092 94047 22902 24919 46226 74380 9196 55570 9614 49483 2459 47024 34300 34300 66138 33069 33069 169029 54652 3669 110708 82736 12625 25425 44686 52215 16904 11439 23872 91955 26038 24329 41588 94745 37898 37898 18949 123004 36901 55352 30751 20935 20935 32830 32830 Bad Debt 124536 124536 Life Insurance Premiums 111675 111675 Recognition Awards 14249 941 1118 12190 Dues and Subscriptions 9843 5119 4724 29781 3380 22275 4126 5133199 2991943 931683 1209573 5467304 4526131 2945409 2402988 45393 57254 198877 93202 19977 105675 27475298 27215041 5018092 5362445 40971473 39669534 313465 433912 4377547 2582849 1771768 1501171 6462780 4517932 X -1894543 -1418498 4178154 5453717 32225082 31116383 34508693 35151602 40971473 39669534 X 438936 -275807 479780 X 0 1 X 1 0 X 25123804 8034243 5154975 6370076 4520407 49203505 25123804 8034243 5154975 6370076 4520407 49203505 21854345 27349160 433142 732310 720388 872830 904836 3663506 52867011 0.51730 0.46830 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 X 26167534 103477 535123 260879 4031854 22513401 25563123 1023628 2442972 2862189 26167534 20816303 2539740 2207080 25563123 21836981 887174 -763804 1144048 20816303 20192293 863972 2024961 1244245 21836981 1.00000 1 0 36517 304 36213 162360 92898 69462 105675 Charitable Remainder Trusts Receivable 3154657 Cash Surrender Value of Life Insurance 2071060 Other Receivables 136728 5362445 X 5775523 -275807 479780 203973 5571550 585 585 5572135 5132614 0 5132614 585 585 5133199 Part IV, Line 2b: On behalf of forty-four orthopaedic organizations, the Foundation accepts contributions for which it performs recordkeeping and provides grants as requested by those organizations. Part V, Line 4: The endowment funds are invested in a well-diversified portfolio and disbursements are made as outlined in an endowment spending policy to support the Foundation's mission. Part X, Line 2: The Foundation, an Illinois nonprofit corporation, is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and applicable state law, except for taxes pertaining to unrelated business income, if any. The Foundation follows the accounting standard on accounting for uncertainty in income taxes, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under the guidance, the Foundation may recognize the tax benefits from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. Examples of tax positions include the tax-exempt status of the Foundation and various positions related to potential sources of unrelated business taxable income. As of December 31, 2014, there were no unrecognized tax benefits identified or recorded as liabilities. The Foundation files Form 990 in the U.S. federal jurisdiction and the State of Illinois. The Foundation is no longer subject to examination by the Internal Revenue Service for years before 2011. Part XI, Line 2d - Other Adjustments: Change in Cash Surrender Value of Life Insurance Policies 121,686. Change in Value of Charitable Remainder Trusts 358,094. 1 Northwestern University Medical School 676 North St Clair Suite 1350 Chicago IL 60611 362167817 501(c)(3) 224442 A Therapeutic Approach to Prevent Smoking-Mediated Bone Healing Inhibition University of Iowa College of Medicine 200 Hawkins Drive Iowa City IA 522421088 426004813 501(c)(3) 150000 Outcome of Surgery for Anterior Shoulder Instability: A Prospective Multi-Center Cohort Study Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York NY 10021 131624182 501(c)(3) 150000 A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur University of Virginia School of Medicine Box 800159 Charlottesville VA 22908 546001796 501(c)(3) 100000 Interaction Between Mesenchymal Stem Cells and T Cells During Osteogenesis Duke University 375 MSRB Research Drive Box 3093 Durham NC 27710 560532129 501(c)(3) 100000 Assessment of Physical Performance, Walking Mechanics, and the Cost-Effectiveness of Revision Total Ankle Replacement Hospital for Special Surgery Cornell University Medical College 535 East 70th Street New York NY 10021 131624135 501(c)(3) 84500 1) Quantification of Mid-Flexion Laxity After Total Knee Replacement; 2) The Effect of Calregulin on Osteoclastogenesis and Ovariectomy-Induced Bone Loss in Mice; 3) Evaluation of Simvastatin-Containing Nanomedicine in Bone Fracture Healing in Old and Young Mice Vanderbilt University School of Medicine Medical Center East Nashville TN 372328774 620476822 501(c)(3) 62000 Real Time In Vivo Tumor and Tumor Bed Assessment After Soft Tissue Sarcoma Excision Using Optical Spectroscopy University of Rochester School of Medicine and Dentistry 601 Elmwood Avenue Box 665 Rochester NY 14642 160743209 501(c)(3) 50000 Defining the Role of BMP Signaling in the Development of Degenerative Disc Diseases University of Iowa College of Medicine 200 Hawkins Drive Iowa City IA 522421088 426004813 501(c)(3) 50000 Scapular Notching in Reverse Shoulder Arthroplasty with Medialized versus Lateralized Implants: A Clinical and Finite Element Study University of Colorado School of Medicine at Denver 4701 East 9th Avenue Box E203 Denver CO 80262 846000555 501(c)(3) 50000 Identification of Therapeutic Targets to Improve Arthroplasty Outcomes in the Presence of Co-Morbid Diabetes Mellitus Thomas Jefferson University Rothman Institute 925 Chestnut Street Philadelphia PA 19107 222620085 501(c)(3) 50000 Engineering Human Fibrocartilage Using Transdifferentiated Tenocytes Columbia University Medical Center 622 West 168th Street PH11 New York NY 10032 135598093 501(c)(3) 50000 The Effect of Calregulin on Osteoclastogenesis and Ovariectomy-Induced Bone Loss in Mice Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland OH 44195 340714585 501(c)(3) 49997 Post-Operative Three-Dimensional Computed Tomography Analysis of Implant Position and Outcome at Minimum Two Year Follow-up Following Total Shoulder Arthroplasty Children's National Medical Center 111 Michigan Avenue NW Washington DC 20010 521640402 501(c)(3) 25000 Genetic Determinants of Peak Bone Mass in Healthy Young Adult Women Washington University School of Medicine 660 S Euclid St Louis MO 63110 430653611 501(c)(3) 20000 Randomized Trial of Alvimopan for the Reduction of Ileus After Long Posterior Spinal Fusion University of Iowa College of Medicine 200 Hawkins Drive Iowa City IA 522421088 426004813 501(c)(3) 20000 Development of a Multi-Center Quality Improvement Tool After Hip Fracture Surgery: A Hospital Based, Risk-Adjusted Pilot Study University of California San Francisco School of Medicine 500 Parnassus Avenue San Francisco CA 94143 946036493 501(c)(3) 20000 The Effect of the Endocrine Disrupting Chemical Bisphenol A (BPA) on Endochronal Ossification in Fracture Repair University of California Irvine 101 The City Drive South Pav III 2nd Floor Rte 81 Orange CA 92868 952226406 501(c)(3) 20000 Schwann Cell-Derived Desert Hedgehog as a Therapeutic Adjunct for Compressive Neuropathies University of California Davis 4860 Y Street Suite 3800 Sacramento CA 95817 946038494 501(c)(3) 20000 The Role of Nox4 as a Mediator of Osteoarthritis and a Potential Target for Treatment Ohio State University 410 West 10th Avenue Columbus OH 43210 381746722 501(c)(3) 20000 Can Physical Examination Predict Patient-Reported Outcomes of ACL Reconstruction? Dartmouth Hitchcock Medical Center One Medical Center Drive Lebanon NH 03756 020222111 501(c)(3) 20000 The Spine Patient Outcomes Research Trial (SPORT) Columbia University Medical Center 622 West 168th Street PH11 New York NY 10032 135598093 501(c)(3) 20000 Matrix Stiffness and Sarcoma Growth: Scientific Implication of Compartments Beth Israel Deaconess Medical Center 330 Brookline Avenue Boston MA 02215 042103881 501(c)(3) 20000 Biomechanical Analysis of Tibiofemoral Contact Pressures After Novel Repair of Meniscus Horizontal Cleavage Tears Washington University School of Medicine 660 S Euclid St Louis MO 63110 430653611 501(c)(3) 16950 Biomechanical Analysis of Tensile Properties and Fiber Alignment in the Anterior Cruciate Ligament to Map Ligament Bundle Design 24 0 Part I, Line 2: The Research Grants Committee is responsible for allocating research funding to advance research in the specialty of orthopaedics and is empowered to establish criteria for the allocation and distribution of philanthropic funds to advance research in the specialty of orthopaedics, implement and conduct an independent peer review process to select research funding recipients, prepare and distribute the necessary promotional information and application forms for research grants and awards and to accept and allocate or decline to allocate, at its sole and absolute discretion, grants and awards for research. One-year grants receive 50% of the funds to start, then 40% after a six-month financial report is received. A final scientific and lay report is required within 60 days after the grant ends, and a final financial report. Once Orthopaedic Research and Education Foundation has all reports, the final 10% of the funds are released. One-time award/educational grant/lectureship grants receive full payment after they are approved. Documentation is in the file for lectureships, educational programs, and awards. Two-or three year grants are paid and spread over the term of the grant. The 10% withheld is the same until all reports are received. These multi-year grants submit annual scientific progress reports which are then reviewed by the original peer review committee member. X X X 0 0 0 0 0 0 0 0 0 Sharon K Mellor PhD CAE Chief Executive Officer 188844 0 12000 0 361 0 38761 0 17267 0 257233 0 0 0 Donna Rebeck CPA CAE CFO/COO 143095 0 6000 0 1249 0 28813 0 21029 0 200186 0 0 0 X 21 171652 Fair Market Value 0 0 1 0 Part I, Column (b): is the number of contributions Form 990, Part III, line 3 The Clinician Development Program was transitioned at the start of 2014 to another orthopaedic not-for-profit organization. Form 990, Part VI, Section B, line 11 The organization's CFO, CEO and Finance Committee review the Form 990. The Form 990 is provided to the Trustees who have the opportunity to review it electronically prior to filing with the IRS. Form 990, Part VI, Section B, line 12c All Board Members annual submission of disclosure statements are on file with the OREF Chief Executive Officer (CEO). The CEO reviews meeting agendas prior to the meeting and notifies leadership of any issues that need to be addressed before the discussion can take place. Any individual who gives notice of potential conflict is to abstain from participating in any item of business which comes before the Board. Form 990, Part VI, Section B, line 15 The Foundation has a formal process to determine the compensation of its CEO. The CEO has ultimate responsibility for implementing the decisions of the Board of Trustees and for supervising the Foundation's management, administration and operations. The process includes the following elements: (1) Review and approval by the Board of Trustees or Compensation Committee; (2) Use comparable compensation data; and (3) Contemporaneous documentation and recordkeeping. Form 990, Part VI, Section C, line 19 The organization made its governing documents, conflict of interest policy, and financial statements available to the public upon request for the same period of disclosure as set forth in IRC section 6104(d). Form 990, Part XI, line 9: Change in Cash Surrender Value of Life Insurance Policies 121,686. Change in Value of Charitable Remainder Trusts 358,094. Charitable Remainder Trusts (5) Charitable Trust IL Orthopaedic Research and Education Foundation T 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0